Restenosis after coronary angioplasty.
The major disadvantage of using percutaneous transluminal coronary angioplasty to treat patients with atherosclerotic coronary disease is the frequent occurrence of restenosis after an initially successful procedure. Studies in animals and histological observations in man have demonstrated that restenosis is characterized by neointimal hyperplasia due to smooth muscle cell proliferation and to the synthesis of extracellular matrix. Improvements in technology or pharmacological interventions have had no significant impact on the rate of restenosis. In spite of our increased understanding of the molecular mechanisms of restenosis. no effective treatment is available at the present time. Gene therapy, which has produced encouraging initial results in experimental models, may provide a solution in the medium term.
Hamon
M
M
Department of Cardiology, University of Lille, France.
Bauters
C
C
McFadden
E P
EP
Wernert
N
N
Lablanche
J M
JM
Dupuis
B
B
Bertrand
M E
ME
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000818:Animals; D001792:Blood Platelets / Q000473:pathology; D003251:Constriction, Pathologic / Q000473:pathology / Q000517:prevention & control / Q000628:therapy; D003327:Coronary Disease / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D003331:Coronary Vessels / Q000293:injuries / Q000473:pathology; D004730:Endothelium, Vascular / Q000473:pathology; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis; D015316:Genetic Therapy; D005822:Genetic Vectors; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D006965:Hyperplasia; D008666:Metalloendopeptidases / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D011817:Rabbits; D012008:Recurrence; D015607:Stents; D013927:Thrombosis / Q000473:pathology; D017539:Tunica Intima / Q000293:injuries / Q000473:pathology
D016326:Extracellular Matrix Proteins; D006133:Growth Substances; D008666:Metalloendopeptidases